Hepatocellular carcinoma and hepatitis C virus infection in Latin America: epidemiology, diagnosis and treatment

Abstract

Hepatocellular carcinoma (HCC) is the most common cancer associated with chronic liver disease and cirrhosis. The most common cause of HCC is chronic hepatitis C virus infection and many studies in Europe, Asia and North America have focused on its etiology, epidemiology, diagnostic tools, and therapeutic options. However, little is known about these issues in Latin America. The aim of this review is to address these aspects of HCC in Latin America. The main risk factors associated with developing HCC in this region are: age, concomitant cirrhosis, hepatitis C infection, obesity and hereditary disease such as hemochromatosis. On the other hand, screening tests and diagnostic methods of HCC are mostly serum alpha fetoprotein quantification, liver ultrasound, computed tomography, magnetic resonance, and histopathology. Novel diagnostic methods include gut microbiota analysis and the use of nanotechnology and they continue to be tested. Finally, according to the Barcelona Clinic Liver Cancer, curative treatments used in HCC patients are mainly liver resection, liver transplantation, and local ablation, each with advantages and disadvantages. In conclusion, clear strategies are urgently needed to understand the extent of HCC and related problems in this part of the world. This review provides greater knowledge of HCC for the proper design of preventive programs by taking into consideration specific characteristics of our population. Also, this review allows for an understanding of individualizing treatments according to the patient’s needs.

Keywords

Liver / hepatitis C / epidemiology / diagnosis / treatment / hepatocellular carcinoma / Latin America

References

[1] Piñero F,Ridruejo E.Hepatocellular carcinoma in Latin America: diagnosis and treatment challenges..World J Gastroenterol2018;24:4224-9 PMCID:PMC6175763

[2] Fassio E,Santa C,Martínez Artola Y.Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study..Ann Hepatol2010;9:63-9

[3] Ferlay J,Dikshit R,Mather C.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012..In J Cancer2015;136:E359-86

[4] Mcglynn KA,London WT.Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability..Clin Liver Dis2015;19:223-38 PMCID:PMC4712629

[5] Méndez-Sánchez N,Alves de Mattos A,Zapata R.Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma..Ann Hepatol2014;13:S4-40

[6] Piñero F,Marciano S,Silva J.Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina..World J Hepatol2018;10:41-50 PMCID:PMC5787683

[7] IARC/WHO. GLOBOCAN 2019: Estimated cancer incidence, mortality and prevalence worldwide in 2019. Cancer today data base, Population Fact Sheets. Available from: https://gco.iarc.fr/today/fact-sheets-populations [Last accessed on 16 Apr 2020]

[8] Piñeiro F,Boteon YL,Marciano S.A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America..Clin Res Hepatol Gastroenterol2018;42:443-52

[9] World Health Organization. Hepatitis B and C in the spotlight, a public health response in the America. 2016. Available from: http://iris.paho.org/xmlui/bitstream/handle/123456789/31449/9789275119297eng.pdf?sequence=5&isAllowed=y [Last accessed on 16 Apr 2020]

[10] Blach S,Manns M,Duberg AS.Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study..Lancet Gastroenterol Hepatol2017;2:161-76

[11] World Health Organization. Global Hepatitis Report, World Health Organization. 2017. Available from: http://www.who.int/hepatitis [Last accessed on 16 Apr 2020]

[12] Centers for Disease Control and Prevention. The ABCs of Hepatitis Fact Sheet. 2016. Available from: www.cdc.gov/hepatitis [Last accessed on 16 Apr 2020]

[13] Liu Z,Yuan H,Cai N.The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention..J Hepatol2019;70:674-83

[14] Zein NN.Clinical significance of hepatitis C virus genotypes..Clin Microbiol Rev2000;13:223-35 PMCID:PMC100152

[15] Kershenobich D,Sánchez-Avila JF,Coelho HS.Trends and projections of hepatitis C virus epidemiology in Latin America..Liver Int2011;31:18-29

[16] Maucort-Boulch D,Franceschi S.Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide..Int J Cancer2018;142:2471-7

[17] Motola-Kuba D,Uribe M.Hepatocellular carcinoma. An overview..Ann Hepatol2006;5:16-24

[18] González Huezo MS.Mexican consensus on the diagnosis and management of hepatocellular carcinoma..Rev Gastroenterol Mex2014;79:250-62

[19] Méndez-Sánchez N,Reyes A,Juárez A.Etiology of liver cirrhosis in Mexico..Ann Hepatol2004;3:30-3

[20] Fattovich G,Zagni I.Hepatocellular carcinoma in cirrhosis: incidence and risk factors..Gastroenterology2004;127:S35-50

[21] Weissenbacher M,Radulich G,Vila M.High seroprevalence of bloodborne viruses among street-recruited injection drug users from Buenos Aires, Argentina..Clin Infect Dis2003;15:S348-52

[22] Guimarães T,Varella D,Castelo A.High prevalence of hepatitis C infection in a Brazilian prisión: identification of risk factors for infection..Braz J Infect Dis2001;5:111-28

[23] Pando MA,Maulen S,Marone R.Epidemiology of human immunodeficiency virus, viral hepatitis (B and C), treponema pallidum, and human T-cell, and human T-cell lymphotropic I/II virus among men who have sex with men in Buenos Aires Argentina..Sex Transm Dis2006;33:307-13

[24] Singal AG,Yopp AC,Marrero JA.The effect of PNPLA3 on fibrosis progression and development of the hepatocellular carcinoma a meta-analysis..Am J Gastroenterol2014;109:325-24 PMCID:PMC5610907

[25] Saab S,Nieto J,Chalasani NP.Nonalcoholic fatty liver disease in Latinos..Clin Gastroenterol Hepatol2016;14:5-12

[26] Nordenstedt H,El-Serag HB.The changing pattern of epidemiology in hepatocellular carcinoma..Dig Liver Dis2010;42:s206-14 PMCID:PMC3392755

[27] Jiwani SS,Hernández-Vásquez A,Basto-Abreu A.The shift of obesity burden by socioeconomic status between 1998 and 2017 in Latin America and the Caribbean: a cross-sectional series study..Lancet Glob Health2019;7:e1644-54

[28] NCD Risk Factor Collaboration (NCD-RisC)Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults..Lancet2017;390:2627-42 PMCID:PMC5735219

[29] Méndez-Sánchez N,Chávez-Tapia NC,Almeda-Valdés P.Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data..Ann Hepatol2005;4:52-5

[30] Bailey MA.Hepatocellular carcinoma: predisposing conditions and precursor lesions..Gastroenterol Clin North Am2002;31:641-62

[31] Marrero JA,Wang Y,Befeler AS.Alpha-protein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma..Gastroenterology2009;137:110-28 PMCID:PMC2704256

[32] El-Serag HB,Chen GJ,Richardson PA.Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA..GUT2011;60:992-7

[33] Marrero JA.Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis..Aliment Pharmacol Ther2009;30:37-47 PMCID:PMC6871653

[34] European Association for the study of the liver, European Organisation for Research and Treatment of CancerEASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma..J Hepatol2012;56:908-43

[35] Heimbach J,Finn RS,Abecassis MM.AASLD guidelines for the treatment of hepatocellular carcinoma..Hepatology2018;67:358-80

[36] Marrero JA,Rajender Reddy K.ACG clinical guideline: the diagnosis and management of focal liver lesions..Am J Gastroenterol2014;109:1328-47

[37] Kudo M,Izumi N,Kadoya M.JSH-consensus-based clinical practice guideline for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan..Liver Cancer2014;3:458-68 PMCID:PMC4531423

[38] Matsui O.Analysis of intranodular hemodynamics of dysplastic nodules in cirrhotic livers..Radiology2001;218:603-5

[39] Ueda K,Nakanuma Y.Vascular supply in adenomatous hyperplasia of the liver and hepatocellular carcinoma: a morphometric study..Hum Pathol1992;23:619-26

[40] Forner A,Ayuso C,Solé M.Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnosis criteria for hepatocellular carcinoma..Hepatology2008;47:97-104

[41] Sangiovanni A,Iavarone M,Forzenigo LV.The diagnosis and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis..Gut2010;59:638-44

[42] Bolondi L,Celli N,Grigioni WR.Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma..Hepatology2005;42:27-34

[43] Hanna RF,Tang A,Brejt SZ.Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma..Abdom Radiol2016;41:71-90

[44] Lee YJ,Lee JS,Park BH.Hepatocellular carcinoma: diagnosis performance of multidetector CT and MR imaging a system review and meta-analysis..Radiology2015;275:97-109

[45] Roberts LR,Zaiem F,Prokop LJ.Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis..Hepatology2018;67:401-21

[46] Kierans AS,Rosenkrantz AB.The diagnosis performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm: a meta-analysis..Radiology2016;278:82-94

[47] Kele PG.Diffusion weighted imaging in the liver..World J Gastroenterol2010;16:1567-76 PMCID:PMC2848365

[48] Miller FH,Siddiqi AJ,Khatri G.Utility of difussion-weighted MRI in distinguishing benign and malignant hepatic lesion..J Magn Reson Imaging2010;32:138-47

[49] Galea N,Taouli B.Liver lesion detection and characterization: role of diffusion-weighted imaging..J Magn Reson Imaging2013;37:1260-76

[50] Van Beers BE,Hussain HK.Primovist, Eovist: what to expect?.J Hepatol2012;57:421-9

[51] Caturelli E,Anti M,Roselli P.Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study..Gut2004;53:1356-62 PMCID:PMC1774185

[52] International Consensus Group for Hepatocellular Neoplasia, The International Consensus Group for Hepatocellular NeoplasiaPathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia..Hepatology2009;49:658-64

[53] Ponziani FR,Gasbarrini A.Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma..Ther Adv Med Oncol2019;11:1758835919848184 PMCID:PMC6535703

[54] Kawai T.The roles of TLRs, RLSs and NLRs in pathogen recognition..Int Immunol2009;21:317-37 PMCID:PMC2721684

[55] Miao EA,Warren SE.TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system..Semin Immunopathol2007;29:275-88

[56] Luedde T.NF-kB in the liver-linking injury, fibrosis and hepatocellular carcinoma..Nat Rev Gastroenterol Hepatol2011;8:108-28 PMCID:PMC3295539

[57] Jung IH,Chung YY,Park YN.Predominant acivation of JAK/STAT3 pathway by interleukin-6 is implicated in hepatocarcinogenesis..Neoplasia2015;17:586-697 PMCID:PMC4547407

[58] Smith DB,Kuiken C,Rice CM.Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updatecrietria and genotype assignment web resource..Hepatology2013;59:318-27 PMCID:PMC4063340

[59] Arca-Lafuente S,Mateo-Cano I,Briz V.Nanotechnology: a reality for diagnosis of HCV infectious disease..J Infect2019;30:30281-6

[60] Hussain MM,Azzazy HME.Unmodified gold nanoparticles for direct and rapid detection of mycobacterium tuberculosis complex..Clin Biochem2013;46:633-7

[61] Gill P,Abdul-tehrani H.Colorimetric detection of helicobacter pylori DNA using isothermal helicase-dependent amplification and gold nanoparticle probes..Diagn Microbiol Infect Dis2008;62:119-24

[62] Carter JR,Kucharski CA,Fraser MJ.A novel dengue virus detection method that couples DNAzyme and gold nanoparticle approaches..Virol J2013;10:201 PMCID:PMC3765938

[63] Liu Y,Wei W,Zhou Z.Colorimetric detection in influenza a virus using antibody-functionalized gold nanoparticles..Analyst2015;140:3989-95

[64] Wang C,Shen X.Development of a nucleic acid lateral flow strip for detection of hepatitis C virus (HCV) core antigen..Nucleosides Nucleotides Nucl Acids2013;32:59-68

[65] Daniele B,Megna AS.a-fetoprotein and ultrasonography screening for hepatocellular carcinoma..Gastroenterology2004;127:S108-12

[66] Fassio E.Consenso y guías Argentinas para la vigilancia, Diagnóstico y Tratamiento del Hepatocarcinoma..Acta Gastroenterol Latinoam2016;46:350-74(in Spanish)

[67] Llovet JM,Bruix J.Prognosis of hepatocellular carcinoma: the BCLC staging classification..Semin Liver Dis1999;19:329-38

[68] Meza-Junco J,Myrna C.Treatment modalities in patients with hepatocellular carcinoma: a restrospective series in a single institution in Mexico..Gastroenterol Hepatol2004;27:11-7

[69] Grazi GL,Pierangeli F,Cescon M.Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value..Ann Surg2001;234:71-8 PMCID:PMC1421950

[70] Poon RT,Ng IO.Significance of resection marging in hepatectomy for hepatocellular carcinoma: a critical reappraisal..Ann Surg2000;23:544-51 PMCID:PMC1421031

[71] Imamura H,Miyagawa Y,Shimada R.Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma..Br J Surg1999;86:1032-38

[72] Hasegawa K,Imamura H,Aoki T.Prognostic impact of anatomic resection for hepatocellular carcinoma..Ann Surg2005;242:252-9 PMCID:PMC1357731

[73] Kosuge T,Takayama T,Shimada K.Long-term results after resection of hepatocellular carcinoma: experience of 480 cases..Hepatogastroenterology1993;40:328-32

[74] Carrilho FJ,Branco F,Aves de Mattos A.Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil..Clinics2010;65:1285-90 PMCID:PMC3020338

[75] Fan ST.Hepatocellular carcinoma- resection or transplant?.Nat Rev Gastroenterol Hepatol2012;9:732-37

[76] Clavien PA,Bossuyt PM,Langer B.Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus coference report..Lacet Oncol2012;13:e11-22 PMCID:PMC3417764

[77] Mazzaferro V,Sposito C,Langer M.Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience..Liver Transpl2011;17:S44-57

[78] Sociedad de Trasplantes de América Latina y el Caribe (Stalyc). Newsletter transplant international figures on donation and transplantation 2016. Available from: https://stalyc.net/utilidades/biblioteca/publicaciones/file/94-newsletter-transplant-22.html [Last accessed on 16 Apr 2020]

[79] Sociedad de Trasplantes de América Latina y el Caribe (Stalyc). Latin America Transplantation Registry Report 2015-2016. Available from: https://www.stalyc.net/registros/file/74-latin-america-transplantation-registry-report-2015-2016.html [Last accessed on 16 Apr 2020]

[80] Inchingolo R,Mariappan M.Locoregional treatments for hepatocellular carcinoma: current evidence and future directions..World J Gastroenterol2019;28:4614-28 PMCID:PMC6718039

[81] N’Kontchou G,Aout M,Grando V.Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis..Hepatology2009;50:1475-83

[82] Lu DS,Raman SS,Lassman C.Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver..Radiology2005;234:954-60

[83] Sato S,Imamura M,Obi S.Power Doopler signals after percutaneous ethanol injection therapy for hepatocellular carcinoma predict local recurrence of tumors: a prospective study using 199 consecutive patients..J Hepatol2001;35:225-34

[84] Lencioni R.Local-regional treatment of hepatocellular carcinoma..Radiology2012;262:43-58

[85] Khan KN,Yamasaki K,Inoue O.Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection..J Hepatol2000;32:269-78

[86] Dou JP,Yu J.Microwave ablation for liver tumors..Abdom Radiol2016;41:650-8

[87] Glassberg MB,Clymer JW,Ferko N.Microwave ablation compared with hepatic resection for the treatmemt of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis..World J Surg Oncol2019;17:98 PMCID:PMC6558848

[88] Doo Song K.Percutaneous cryoablation for hepatocellular carcinoma..Clin Mol Hepatol2016;22:509-15 PMCID:PMC5266346

[89] Zimmerman A,Charpentier KP.Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives..J Hepatocell Carcinoma2017;13:49-58 PMCID:PMC5357069

[90] Llovet JM.Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival..Hepatology2003;37:429-42

[91] Bouvry C,Edeline J,Loyer P.Transarterial radioembolization (TARE) agents beyond 90Y microspheres..Biomed Res International2018;2018:1-14

[92] Hsieh TC,Sun SS,Kao CH.Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review..Biomedicine2016;6:19 PMCID:PMC5138159

[93] Bruix J.Management of hepatocellular carcinoma: an up date..Hepatology2011;53:1020-2 PMCID:PMC3084991

[94] Leathers JS,Prieto J,Gonzalez-Ballerga E.Sorafenib for treatment of hepatocellular carcinoma: a survival analysis from the south american liver research network..J Clin Gastroenterol2019;53:464-9

[95] Greten TF,Li G.Targeted and immune-based therapies for hepatocellular carcinoma..Gastroenterol2019;156:510-24 PMCID:PMC6340758

[96] De Mattia E,Guardascione M,Raimo TD.Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma..World J Gastroenterol2019;25:3870-96 PMCID:PMC6689804

[97] Bruix J,Merle P,Huang YH.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet2017;389:56-66

[98] Abou-Alfa GK,Cheng AL,Rimassa L.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma..N Engl J Med2018;379:54-63

[99] Turkes F.Ramucirumab and its use in the treatment of hepatocellular carcinoma..Future Oncol2019;15:979-88

[100] Finkelmeier F,Trojan J.Nivolumab for the treatment of hepatocellular carcinoma..Expert Rev Anticancer Ther2018;18:1169-75

[101] Wang J,Tang X,Qiao Y.Doxorubicin induces apoptosis by targeting Madcam 1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells..Oncotarget2015;6:24075-91 PMCID:PMC4695171

[102] Zhou Y,Li F,Wang Y.Doxorubicin and ABT-199 coencapsulated nanocarriers for targeted delivery and synergistic treatment against hepatocellular carcinoma..J Nanomat2019;2019:13

[103] Zhuang L,Yang Z.Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis..PloS One2013;8:e61361 PMCID:PMC3775819

[104] George PM,Alazawi W,Mitchell JA.Pharmacology and therapeutic potential of interferons..Pharmacol Ther2012;135:44-53

[105] Nishiguchi S,Nakatani S,Takeda T.Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis..Lancet1995;346:1051-5

[106] Bruno S,Colombo M,Benvegnú L.Sustained virological response to interferon-alpha is associated with improved outcome in HVC-related cirrhosis: a retrospective study..Hepatology2007;45:579-87

[107] Baumert TF,Lim JK.Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges..Gastroenterology2019;156:431-45 PMCID:PMC6446912

[108] Piñero F,Chagas A,Marciano S.Direct-acting antivirals and hepatocellular carcinoma: no evidence of higher waitlist progression or post-transplant recurrence..Liver Transpl2020;epub ahead of print. doi: 10.1002/lt.25744

[109] Mendizabal M,Ridruejo E,Anders M.Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents..Clin Gastroenterol Hepatol2020;28:30263-9